CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 261 enrolled
Drug / intervention
fluticasone propionate inhalation solution +4 moredrug
Likely dose
fluticasone propionate inhalation solution 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01687296
NCT01687296Phase 3Completed

A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediatric and Adolescent Subjects (Aged 4 to 16 Years) With an Acute Exacerbation of Asthma

GlaxoSmithKline·interventional·Posted Sep 18, 2012·Updated Jun 20, 2018

In Brief

A Phase 3 clinical trial evaluating fluticasone propionate inhalation solution, oral prednisone, and 3 other interventions for Asthma. Completed, enrolled 261 participants across 11 sites.

Detailed Summary

This is a multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with oral prednisone administered for 7 days to Chinese pediatric and adolescent subjects (aged 4 to 16 years) with an acute exacerbation of asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2012
Enrollment StartNov 12, 2012
Primary CompletionJun 1, 2013
Study CompletionJun 21, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.8 years ago

Interventions

fluticasone propionate inhalation solutiondrug

2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days

oral prednisonedrug

once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days

placebo inhalation solutiondrug

4ml 0.9% saline nebulized twice daily

placebo tabletdrug

placebo soluble tablet, oral ,once daily

salbutamoldrug

Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.